Dictionary
Thesaurus
Reference
Translate
Web
Nearby Entries
CDP323 - 1 reference results
Wikipedia
CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

In October 2006, UCB S.A. and Biogen Idec announced a collaboration to jointly develop and commercialize CDP323 for the treatment of multiple sclerosis and other potential indications.

Mechanism of action

The mechanism of action of CDP323 is believed to rely on preventing immune cells to migrate from blood vessels through the vessel walls to reach various inflamed tissues, including the brain. This mechanism is thought to prevent overshooting immune reactions and subsequent tissue damage as seen during uncontrolled immune cell migration as in multiple sclerosis. CDP323 has the same mechanism of action as the monoclonal antibody natalizumab.

Results in animal models

CDP323 was investigated in chronic experimental autoimmune encephalomyelitis (EAE) in mice. The drug was effective when given prophylactically (i.e., before the disease was induced in mice) and when given therapeutically (i.e., after outbreak of the disease) and reduced the disease severity significantly.

Clinical development

The safety, tolerability, and pharmacokinetic profile of CDP323 have been evaluated in 75 female and male healthy volunteers in three separate Phase 1 studies. CDP323 was well tolerated at oral doses up to 1000 mg given twice daily for 7 consecutive days with an adverse event profile comparable to that observed with placebo. There was no gender effect. The oral administration resulted in inhibition of VCAM-1 binding which could be maintained throughout a 12 or 24 hour dose interval at well tolerated doses

A Phase 2 study commenced in June 2007 in Europe and in the US. The study intends to enroll over 200 patients with relapsing MS who have failed earlier treatment with an interferon-beta and will compare two doses of the drug to placebo over a period of six months. The results are expected by the end of 2008.,

References

External links

Wikipedia, the free encyclopedia © 2001-2006 Wikipedia contributors (Disclaimer)
This article is licensed under the GNU Free Documentation License.
Last updated on Sunday August 31, 2008 at 17:37:30 PDT (GMT -0700)
View this article at Wikipedia.org - Edit this article at Wikipedia.org - Donate to the Wikimedia Foundation

Share :Share This: digg.comShare This: www.stumbleupon.comShare This: del.icio.usShare This: FacebookShare This: favorites.live.comShare This: www.technorati.comShare This: furl.netShare This: www.myspace.comShare This: www.google.comShare This: myweb2.search.yahoo.comShare This: myjeeves.ask.com
Search another word or see CDP323 on Dictionary | Thesaurus | Translate
Get your FREE Subscription to Dictionary.com Word of the Day
The FREE Dictionary.com Toolbar
Dictionary Thesaurus Reference
The answers are right on your browser and just a click away with Dictionary.com Toolbar.